VRAX (Virax Biolabs Group) Total Equity : $8.42 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Total Equity?

Virax Biolabs Group's total equity for the quarter that ended in Sep. 2024 was $8.42 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Virax Biolabs Group Total Equity Historical Data

The historical data trend for Virax Biolabs Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Total Equity Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Total Equity

-1.22

-0.83

-1.20

8.90

5.14

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Total Equity	Get a 7-Day Free Trial					4.16	8.90	6.11	5.14	8.42

Virax Biolabs Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Virax Biolabs Group's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	5.484	-	0.345
	=	5.14

Virax Biolabs Group's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	9.443	-	1.026
	=	8.42

Virax Biolabs Group Total Equity Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.